KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GoodRx Holdings (GDRX) Shares Outstanding (2019 - 2025)

GoodRx Holdings' Shares Outstanding history spans 7 years, with the latest figure at $341.1 million for Q4 2025.

  • For Q4 2025, Shares Outstanding fell 10.91% year-over-year to $341.1 million; the TTM value through Dec 2025 reached $341.1 million, down 10.91%, while the annual FY2025 figure was $341.1 million, 10.91% down from the prior year.
  • Shares Outstanding for Q4 2025 was $341.1 million at GoodRx Holdings, roughly flat from $341.2 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $400.6 million in Q4 2021 and bottomed at $341.1 million in Q4 2025.
  • The 5-year median for Shares Outstanding is $394.7 million (2021), against an average of $383.6 million.
  • The largest annual shift saw Shares Outstanding surged 71.58% in 2021 before it dropped 10.91% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $400.6 million in 2021, then dropped by 0.88% to $397.0 million in 2022, then decreased by 0.74% to $394.1 million in 2023, then fell by 2.86% to $382.8 million in 2024, then dropped by 10.91% to $341.1 million in 2025.
  • Per Business Quant, the three most recent readings for GDRX's Shares Outstanding are $341.1 million (Q4 2025), $341.2 million (Q3 2025), and $352.8 million (Q2 2025).